COVID-19对D-二聚体诊断肺栓塞敏感性的影响
该多中心回顾性观察队列研究纳入5家急诊科1158例同时完成CTPA、D-二聚体和COVID-19检测的急诊患者,比较COVID-19阳性与阴性患者D-二聚体诊断PE的检验特征。COVID-19阳性患者敏感性100%(95%CI 87.6%-100%)、特异性11.9%、NPV 100%;阴性患者敏感性97.6%(95%CI 91.5%-99.7%)、特异性14.4%、NPV 98.3%。两种检测方法的ROC曲线下面积在两组间相近。结论认为合并COVID-19未显著改变D-二聚体对PE的敏感性,但能否单凭D-二聚体安全排除PE尚需进一步研究。
要点
- COVID-19阳性患者D-二聚体诊断PE敏感性100%(95%CI 87.6%-100%),NPV 100%,与阴性患者敏感性97.6%相近。
- COVID-19阳性患者特异性仅11.9%(95%CI 7.9%-17.1%),阴性患者14.4%,提示阳性结果对PE的确认价值有限。
- 检测1在COVID-19阳性患者AUC 0.76(95%CI 0.68-0.83),阴性0.73(95%CI 0.69-0.77);检测2分别为0.85和0.80。
- 检测1阈值从0.50 FEU提高至0.67 FEU时维持100%敏感性,特异性由18.7%升至29%;检测2阈值从230 DDU提高至662 DDU时维持100%敏感性,特异性由6.1%升至59%。
- 原文结论明确:能否单凭D-二聚体在疑似或确诊COVID-19患者中安全排除PE,或调整D-二聚体阈值是否有管理价值,仍需进一步研究。
适用人群与场景
- 5家城市及郊区急诊科中,单次就诊内同时完成CTPA、D-二聚体和COVID-19检测的所有急诊患者,共1158例次纳入分析。
- 研究时段为2019年12月1日至2020年10月22日。
诊断标准与关键阈值
- 原文未提及PE的诊断标准名称及具体界值。
- 原文提及检测1以FEU(纤维蛋白原等效单位)报告,检测2以DDU(D-二聚体单位)报告;检测1基线阈值为0.50 FEU,检测2基线阈值为230 DDU。
处置流程与药物剂量
- 原文未提及具体处置流程或药物剂量方案。
红旗征与不能漏的情况
- 原文未提及红旗征或需要立刻处理的情况。
研究设计与关键结果
- 研究类型为多中心回顾性观察队列研究,覆盖同一医疗系统内5家城市及郊区急诊科,共1158例次患者就诊符合分析标准。
- COVID-19阳性患者D-二聚体诊断PE敏感性100%(95%CI 87.6%-100%),特异性11.9%(95%CI 7.9%-17.1%),NPV 100%。
- COVID-19阴性患者敏感性97.6%(95%CI 91.5%-99.7%),特异性14.4%(95%CI 12.1%-17%),NPV 98.3%(95%CI 93.8%-99.6%)。
- 检测1 AUC:COVID-19阳性0.76(95%CI 0.68-0.83),阴性0.73(95%CI 0.69-0.77);检测2 AUC:阳性0.85(95%CI 0.77-0.92),阴性0.80(95%CI 0.77-0.84)。
- ROC曲线显示检测1阈值由0.50 FEU提高至0.67 FEU时维持100%敏感性,特异性由18.7%升至29%;检测2阈值由230 DDU提高至662 DDU时维持100%敏感性,特异性由6.1%升至59%。
证据类型、等级与局限
- 证据类型为多中心回顾性观察队列研究。
- 局限:回顾性设计;仅覆盖同一医疗系统的5家急诊科;原文结论指出能否单凭D-二聚体在疑似或确诊COVID-19患者中安全排除PE仍需进一步研究。
对床旁实践的改变
- 原文结果提示合并COVID-19未显著改变D-二聚体对PE的敏感性,不应仅因COVID-19阳性而认为D-二聚体敏感性下降。
- COVID-19阳性患者D-二聚体特异性仅11.9%,阳性结果对PE的确认价值有限,需结合CTPA等进一步评估。
- 原文明确指出能否单凭D-二聚体在疑似或确诊COVID-19患者中安全排除PE尚需进一步研究,不应据此直接改变排除PE的决策。
- 原文提及调整D-二聚体阈值(检测1至0.67 FEU、检测2至662 DDU)可维持100%敏感性并提高特异性,但仅为ROC曲线观察,尚未经前瞻性验证用于管理决策。
指南或共识出处
- 原文未提及指南或共识名称;来源为Acad Emerg Med发表的原始研究。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: This study seeks to evaluate the test characteristics of D-dimer for pulmonary embolism (PE) in patients with a concurrent diagnosis of COVID-19. We hypothesized that the sensitivity of D-dimer for PE at current institutional cut points would be similar to those without COVID-19.
METHODS: This is a multicenter retrospective observational cohort study across five urban and suburban EDs in the same health care system. The electronic health record was queried for all computed tomography pulmonary angiography (CTPA) studies from December 1, 2019, to October 22, 2020. All ED patients who underwent CTPA had D-dimer and COVID-19 testing completed in a single encounter were included in the study. Baseline demographics were obtained. Test characteristics of D-dimer for PE were calculated for patients with and without COVID-19. Additionally, receiver operator characteristics (ROC) curves were constructed for two different D-dimer assays.
RESULTS: There were 1158 patient encounters that met criteria for analysis. Performance of D-dimer testing for PE was similar between COVID-19-positive and -negative patients. In COVID-19-positive patients, the sensitivity was 100% (95% confidence interval [CI] = 87.6%-100%), specificity was 11.9% (95% CI = 7.9%-17.1%), and negative predictive value (NPV) was 100%. In COVID-19-negative patients the sensitivity was 97.6% (95% CI = 91.5%-99.7%), specificity was 14.4% (95% CI = 12.1%-17%), and NPV was 98.3% (95% CI = 93.8%-99.6%). For assay 1 the area under the curve (AUC) for COVID-19-positive patients was 0.76 (95% CI = 0.68-0.83), and for COVID-19-negative patients, 0.73 (95% CI = 0.69-0.77). For assay 2, AUC for COVID-19-positive patients was 0.85 (95% CI = 0.77-0.92), and for COVID-19-negative patients, 0.80 (95% CI = 0.77-0.84). Inspection of the ROC curve for assay 1 revealed that 100% sensitivity was maintained up to a threshold of 0.67 FEU (fibrinogen equivalent units; from 0.50 FEU) with an increase in specificity to 29% (from 18.7%), and for assay 2, 100% sensitivity was maintained up to a threshold of 662 D-dimer units (DDU; from 230 DDU) with an increased specificity to 59% (from 6.1%).
CONCLUSION: Results from this multicenter retrospective study did not find a significant difference in sensitivity of D-dimer for PE due to concomitant COVID-19 infection. Further study is required to determine if PE can safely be excluded based on D-dimer results alone in patients with suspected or proven COVID-19 or if adjusted D-dimer levels could have a role in management.
参考来源
- Elberts SJ, Bateman R, Koutsoubis A, et al. The impact of COVID-19 on the sensitivity of D-dimer for pulmonary embolism. Acad Emerg Med. 2021. PMID: 34425044. doi:10.1111/acem.14348
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。